These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 24156243)

  • 21. The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism.
    Patel AA; Ogden K; Mody SH; Bookhart B
    J Med Econ; 2015 May; 18(5):323-32. PubMed ID: 25557176
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis of rivaroxaban for treatment and secondary prevention of venous thromboembolism in the Netherlands.
    Heisen M; Treur MJ; Heemstra HE; Giesen EBW; Postma MJ
    J Med Econ; 2017 Aug; 20(8):813-824. PubMed ID: 28521540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: a US perspective.
    de Lissovoy G; Subedi P
    Am J Manag Care; 2002 Dec; 8(12):1082-8. PubMed ID: 12500884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticoagulation prophylaxis in orthopedic surgery: an efficiency frontier approach.
    Migliaccio-Walle K; Rublee D; Simon TA
    Postgrad Med; 2012 Jan; 124(1):41-9. PubMed ID: 22314113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
    Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
    Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-Effectiveness of Different Strategies for the Prevention of Venous Thromboembolism After Total Hip Replacement in China.
    Yan X; Gu X; Xu Z; Lin H; Wu B
    Adv Ther; 2017 Feb; 34(2):466-480. PubMed ID: 28000167
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patient-reported treatment satisfaction with oral rivaroxaban versus standard therapy in the treatment of pulmonary embolism; results from the EINSTEIN PE trial.
    Prins MH; Bamber L; Cano SJ; Wang MY; Erkens P; Bauersachs R; Lensing AW
    Thromb Res; 2015 Feb; 135(2):281-8. PubMed ID: 25483215
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist.
    Bamber L; Muston D; McLeod E; Guillermin A; Lowin J; Patel R
    Thromb J; 2015; 13():20. PubMed ID: 26074735
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden.
    Ryttberg L; Diamantopoulos A; Forster F; Lees M; Fraschke A; Björholt I
    Expert Rev Pharmacoecon Outcomes Res; 2011 Oct; 11(5):601-15. PubMed ID: 21958104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of patients with acute deep vein thrombosis and/or pulmonary embolism: efficacy and safety of non-VKA oral anticoagulants in selected populations.
    Prandoni P
    Thromb Res; 2014 Aug; 134(2):227-33. PubMed ID: 24875390
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain.
    Monreal M; Folkerts K; Diamantopoulos A; Imberti D; Brosa M
    Thromb Haemost; 2013 Nov; 110(5):987-94. PubMed ID: 23965805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prolonged enoxaparin therapy to prevent venous thromboembolism after primary hip or knee replacement. A cost-utility analysis.
    Haentjens P; De Groote K; Annemans L
    Arch Orthop Trauma Surg; 2004 Oct; 124(8):507-17. PubMed ID: 15365714
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.
    Cohen AT; Dobromirski M
    Thromb Haemost; 2012 Jun; 107(6):1035-43. PubMed ID: 22371186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-Effectiveness of Dabigatran Compared to Vitamin-K Antagonists for the Treatment of Deep Venous Thrombosis in the Netherlands Using Real-World Data.
    van Leent MW; Stevanović J; Jansman FG; Beinema MJ; Brouwers JR; Postma MJ
    PLoS One; 2015; 10(8):e0135054. PubMed ID: 26241880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting.
    Jugrin AV; Hösel V; Ustyugova A; De Francesco M; Lamotte M; Sunderland T
    J Med Econ; 2016; 19(1):1-10. PubMed ID: 26390231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of rivaroxaban compared with enoxaparin plus warfarin for the treatment of hospitalised acute deep vein thrombosis in China.
    Yang L; Wu J
    BMJ Open; 2020 Jul; 10(7):e038433. PubMed ID: 32737096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Post-thrombotic syndrome in patients treated with rivaroxaban or enoxaparin/vitamin K antagonists for acute deep-vein thrombosis. A post-hoc analysis.
    Cheung YW; Middeldorp S; Prins MH; Pap AF; Lensing AW; Ten Cate-Hoek AJ; Villalta S; Milan M; Beyer-Westendorf J; Verhamme P; Bauersachs RM; Prandoni P;
    Thromb Haemost; 2016 Sep; 116(4):733-8. PubMed ID: 27583311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness.
    Kansal AR; Sharma M; Bradley-Kennedy C; Clemens A; Monz BU; Peng S; Roskell N; Sorensen SV
    Thromb Haemost; 2012 Oct; 108(4):672-82. PubMed ID: 22898892
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of venous thromboembolism with rivaroxaban in relation to body weight. A sub-analysis of the EINSTEIN DVT/PE studies.
    Di Nisio M; Vedovati MC; Riera-Mestre A; Prins MH; Mueller K; Cohen AT; Wells PS; Beyer-Westendorf J; Prandoni P; Bounameaux H; Kubitza D; Schneider J; Pisters R; Fedacko J; Fontes-Carvalho R; Lensing AW
    Thromb Haemost; 2016 Sep; 116(4):739-46. PubMed ID: 27535349
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrences.
    Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
    BMC Health Serv Res; 2017 Jan; 17(1):74. PubMed ID: 28114939
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.